IL-8 secretion in primary cultures of prostate cells is associated with prostate cancer aggressiveness
Yves Fradet(Centre hospitalier universitaire de Québec), Vincent Fradet(Centre hospitalier universitaire de Québec)
Cited by 35
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|645
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
|Annals of Oncology|2019|484
Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)
|European Urology|2014|273
Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies.
|Proceedings of the National Academy of Sciences|1984|273